Clover Health shareholders elect directors, approve say-on-pay, ratify E&Y at 2026 meeting

Proposal 2: Non-binding advisory vote to approve the compensation of the Company's Named Executive Officers for 2025. The stockholders vote to approve, on a non-binding advisory basis, the compensation of the Company's Named Executive Officers for 2025. The results of the vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTE 1,003,065,402 9,811,825 1,663,812 177,790,033

Proposal 1: Election of Three Class II Directors. Demetrios L. Kouzoukas, Andrew Toy and Thomas L. Tran were each elected to the Company’s Board of Directors as Class II directors, to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified. The results of the election were as follows: FOR WITHHELD BROKER NON-VOTE Demetrios L. Kouzoukas 1,003,131,251 11,409,888 177,790,033 Andrew Toy 1,011,117,814 3,423,325 177,790,033 Thomas L. Tran 996,918,879 17,622,260 177,790,033

Proposal 3: Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the vote were as follows: FOR AGAINST ABSTAIN 1,188,467,663 2,471,606 1,391,903